Pt-ATP as an antineoplastic agent in an experimental mice model system.
The antineoplastic activity of a platinum complex K4 (Pt Cl2 ATP) (Pt-ATP) has been investigated in transplantable tumors, both in an ascitic and solid (Ehrlich ascites carcinoma) tumor model. It has been observed that the drug at the total dose of 10 mg/kg body weight successfully inhibited the tumor burden both in ascitic and solid tumor system and subsequently increased the host's life span. An assessment of the in vitro (3H) thymidine incorporation into TCA precipitable material of EAC tumor cells done in the presence of Pt-ATP indicates that the drug inhibits (3H) thymidine incorporation in tumor cells. The drug has no appreciable toxic effect on the peripheral blood cells as well as bone marrow and spleenic cellularity.
Pal
S
S
Department of Cell Biology, Chittaranjan National Cancer Institute, Calcutta, India.
Mukherjea
K
K
Bhattacharya
R
R
Maity
P
P
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002945:Cisplatin / Q000494:pharmacology* / Q000633:toxicity; D004195:Disease Models, Animal; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000633:toxicity
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C069451:platinum dichloride-adenosine triphosphate complex; D000255:Adenosine Triphosphate; D002945:Cisplatin